terazosin has been researched along with Syncope in 4 studies
Terazosin: induces decreased blood pressure; used in the treatment of benign prostatic hyperplasia
Syncope: A transient loss of consciousness and postural tone caused by diminished blood flow to the brain (i.e., BRAIN ISCHEMIA). Presyncope refers to the sensation of lightheadedness and loss of strength that precedes a syncopal event or accompanies an incomplete syncope. (From Adams et al., Principles of Neurology, 6th ed, pp367-9)
Excerpt | Relevance | Reference |
---|---|---|
"We describe a 71-year-old male patient who developed acute myocardial infarction (AMI) due to a dynamic left ventricular outflow tract obstruction induced by terazosin." | 7.83 | Myocardial infarction induced by oral terazosin in a patient with predisposing structural cardiomyopathy: case report. ( Ferrando-Castagnetto, F; Lluberas, N; Martínez, F; Vidal Margenat, A; Vignolo, G, 2016) |
"We describe a 71-year-old male patient who developed acute myocardial infarction (AMI) due to a dynamic left ventricular outflow tract obstruction induced by terazosin." | 3.83 | Myocardial infarction induced by oral terazosin in a patient with predisposing structural cardiomyopathy: case report. ( Ferrando-Castagnetto, F; Lluberas, N; Martínez, F; Vidal Margenat, A; Vignolo, G, 2016) |
"Treatment of benign prostatic hyperplasia (BPH) with nonselective alpha1 antagonists such as terazosin, doxazosin, and prazosin results in blood pressure reduction due to vasodilation." | 3.71 | Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study. ( Chao, J; Chrischilles, E; Gilden, D; Kreder, KJ; Rubenstein, L; Shah, H, 2001) |
"The safety of terazosin, an effective agent for the treatment of hypertension, was assessed by analyzing data from 1,006 hypertensive patients who were enrolled in short-term and/or long-term studies." | 3.67 | Overall safety of terazosin as an antihypertensive agent. ( Glassman, HN; Jordan, DC; Luther, RR; Sperzel, WD, 1986) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (25.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ohyama, K | 1 |
Hori, Y | 1 |
Sugiura, M | 1 |
Vidal Margenat, A | 1 |
Ferrando-Castagnetto, F | 1 |
Martínez, F | 1 |
Lluberas, N | 1 |
Vignolo, G | 1 |
Chrischilles, E | 1 |
Rubenstein, L | 1 |
Chao, J | 1 |
Kreder, KJ | 1 |
Gilden, D | 1 |
Shah, H | 1 |
Sperzel, WD | 1 |
Glassman, HN | 1 |
Jordan, DC | 1 |
Luther, RR | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
The Effects of Systemic Alfuzosin and Tamsulosin Hydrochloride on Choroidal Thickness and Pupil Diameter Sizes in Cases With Benign Prostatic Hyperplasia[NCT03144596] | Phase 4 | 63 participants (Actual) | Interventional | 2015-10-29 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
4 other studies available for terazosin and Syncope
Article | Year |
---|---|
Evaluation of syncope association with α
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Doxazosin; Humans; Hypertension; Indoles; Male; Midd | 2019 |
Myocardial infarction induced by oral terazosin in a patient with predisposing structural cardiomyopathy: case report.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Angina Pectoris; Cardiomyopathies; Coronary Angiograp | 2016 |
Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study.
Topics: Accidental Falls; Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Cohort Studies; Comor | 2001 |
Overall safety of terazosin as an antihypertensive agent.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Asthenia; Body Weight; Dizziness; Female; Hea | 1986 |